Abstract
Acute Lymphoblastic Leukemia (ALL) is the most common hematologic malignancy in childhood. It's a heterogeneous disease and despite advances in treatment approximately 20% of patients have relapse or death indicating the need for differentiated therapies for this group. The analysis of genetic and epigenetic abnormalities may enable a more accurate diagnosis and the development …